Our history

Home » About us » Our history

Since the 1980s, we’ve been focused on translational science. It started with technology transfer services for the Medical Research Council (MRC) – something we still do today alongside providing scientific support, advice and funding. 

The sale of a portion of our royalties in the cancer drug Keytruda® (pembrolizumab) gave us financial independence and our status as a ‘self-funded’ medical research charity.

Today, we use the returns from our investment portfolio and a few additional sources of income to fund everything we do.  



Our work started as the Medical Research Council (MRC) Liaison Office  


Established as a charity and a company limited by guarantee – MRC Collaborative Centre  


Changed our name to Medical Research Council Technology 


Joined a drug discovery collaboration, the Dementia Consortium, with Alzheimer’s Research UK for serious diseases


MRC Technology officially rebranded as LifeArc


Our Philanthropic Fund and Seed Fund launched


We sold a portion of our royalty interest in the cancer drug, Keytruda® (pembrolizumab)


Provided more than £27 million to fund the search for new medicines and diagnostics to tackle COVID-19


New strategy, ‘Making life science life changing’ outlined


Our first Translational Challenges – Chronic Respiratory Infection and Motor Neuron Disease – announced


Our 3 Global Health Translational Challenges and our Rare Disease Translational Challenge launched, our final challenge, Childhood Cancer, was announced

Female Patient And Nurse Have Consultation In Hospital Room

Want to know more about our vision and strategy?

WordPress development by Andy White using PorterWP